Skip to main content
Premium Trial:

Request an Annual Quote

New Health Plans Sign on for McKesson's Solutions for MDx, Genetic Testing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Healthcare solutions firm McKesson announced last week the licensing of its molecular and genetic diagnostic management solutions to three health plans, bringing the total number of managed care organizations using its services to 44.

Molina Healthcare, Paramount Healthcare, and Providence Health Plans, part of the five-state Providence Health & Services, are the newest plans to use McKesson's offerings in order to "manage the enormous growth, complexity, and costs associated with molecular and genetic testing," McKesson said in a statement.

"As Molina watches the continued growth of personalized medicine and genetic testing, we are excited about what these new developments mean for our members and for the way healthcare works," Michael Siegel, vice president of utilization management and quality improvement for Molina, said. "However, the area of molecular diagnostics is a difficult one to manage because it's evolving so quickly and there is a constant influx of new tests."

McKesson's solutions will help Molina manage use of such tests and to understand the evidence supporting use of the tests," Siegel added.

McKesson's molecular and genetic testing management offerings "align health plans, ordering physicians, and clinical labs to simplify" test utilization, a spokeswoman for the company told GenomeWeb Daily News in an e-mail. By using its offerings, health plans can determine the medical appropriateness of test orders for each specific patient clinical scenario.

"We can then codify health plan coverage rules for each test, including whether tests require preauthorization, genetic counseling, or notification, as well as which in-network labs are most appropriate to perform certain tests," the spokeswoman said.

McKesson added that the demand for molecular and genetic testing is rising. The market is currently estimated at $7 billion with an annual growth rate of 15 to 20 percent.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.